About Us
COVID-19 has been the most significant global health crisis of our lifetime. As we enter a new and uncertain phase of this current pandemic it is clear that, collectively we must learn from past failures, prioritize pandemic preparedness and invest in innovative science so that we are better prepared for what comes next.
We founded Pardes Biosciences to help stop the COVID-19 pandemic and prevent the next, so patients everywhere can get well sooner.
OUR SCIENCE
Prioritizing Pandemic Preparedness
Our scientists harnessed structure-based drug design and modern chemistry approaches to discover pomotrelvir, a novel direct-acting oral antiviral treatment for SARS-CoV-2, the virus responsible for COVID-19, as well as several potent next generation main protease (Mpro) inhibitors with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering.
PIPELINE
Antivirals for What Comes Next
We have advanced our lead product candidate, pomotrelvir, from concept through phase 2 testing in under three years. The phase 2 trial enrolled 242 otherwise healthy, vaccinated SARS-CoV-2 test-positive patients. In addition, our research efforts have generated a number of highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering.
Follow the latest news on Pardes Biosciences, Inc.